Cargando…
Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder defined by left ventricular hypertrophy that cannot be explained by another cardiac or systemic disease. There is a general lack of knowledge about patients’ perspectives on the symptoms and day-to-day limitations they ex...
Autores principales: | Zaiser, Erica, Sehnert, Amy J., Duenas, Ashley, Saberi, Sara, Brookes, Ella, Reaney, Matthew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708573/ https://www.ncbi.nlm.nih.gov/pubmed/33259041 http://dx.doi.org/10.1186/s41687-020-00269-8 |
Ejemplares similares
-
Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument
por: Reaney, Matthew, et al.
Publicado: (2022) -
Longitudinal Psychometric Analysis of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Using Outcomes from the Phase III EXPLORER-HCM Trial
por: Reaney, Matthew, et al.
Publicado: (2022) -
The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review
por: Edelberg, Jay M., et al.
Publicado: (2022) -
Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire
por: Capota, Razvan, et al.
Publicado: (2020) -
Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
por: Braunwald, Eugene, et al.
Publicado: (2023)